

# Henning Walczak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5416721/publications.pdf>

Version: 2024-02-01

185  
papers

35,416  
citations

4942

84  
h-index

3997

176  
g-index

191  
all docs

191  
docs citations

191  
times ranked

35338  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of ADAM17 impairs endothelial cell necroptosis and blocks metastasis. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	35
2	Compound heterozygous variants in <i>OTULIN</i> are associated with fulminant atypical late-onset ORAS. <i>EMBO Molecular Medicine</i> , 2022, 14, e14901.	3.3	14
3	Spleen tyrosine kinase mediates innate and adaptive immune crosstalk in SARS-CoV-2 mRNA vaccination. <i>EMBO Molecular Medicine</i> , 2022, 14, .	3.3	7
4	TRAIL-receptor 2 is a novel negative regulator of p53. <i>Cell Death and Disease</i> , 2021, 12, 757.	2.7	10
5	Dual roles for LUBAC signaling in thymic epithelial cell development and survival. <i>Cell Death and Differentiation</i> , 2021, 28, 2946-2956.	5.0	4
6	Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers. <i>Cell Death and Differentiation</i> , 2021, , .	5.0	10
7	An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer. <i>Cell Death Discovery</i> , 2020, 6, 14.	2.0	18
8	Death Receptors and Their Ligands in Inflammatory Disease and Cancer. <i>Cold Spring Harbor Perspectives in Biology</i> , 2020, 12, a036384.	2.3	27
9	Cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2/M Checkpoint through Cleavage of USP28. <i>Molecular Cell</i> , 2020, 77, 970-984.e7.	4.5	54
10	M1-linked ubiquitination by LUBEL is required for inflammatory responses to oral infection in <i>Drosophila</i> . <i>Cell Death and Differentiation</i> , 2019, 26, 860-876.	5.0	50
11	Linear ubiquitination at a glance. <i>Journal of Cell Science</i> , 2019, 132, .	1.2	65
12	Endothelial Cell Killing by TAK1 Inhibition: A Novel Anti-angiogenic Strategy in Cancer Therapy. <i>Developmental Cell</i> , 2019, 48, 127-128.	3.1	2
13	Cell Death and Inflammation – A Vital but Dangerous Liaison. <i>Trends in Immunology</i> , 2019, 40, 387-402.	2.9	73
14	RIPK1 and death receptor signaling drive biliary damage and early liver tumorigenesis in mice with chronic hepatobiliary injury. <i>Cell Death and Differentiation</i> , 2019, 26, 2710-2726.	5.0	23
15	LUBAC is essential for embryogenesis by preventing cell death and enabling haematopoiesis. <i>Nature</i> , 2018, 557, 112-117.	13.7	168
16	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. <i>Cell Death and Differentiation</i> , 2018, 25, 486-541.	5.0	4,036
17	Sterile Inflammation Fuels Gastric Cancer. <i>Immunity</i> , 2018, 48, 481-483.	6.6	7
18	Paving TRAIL's Path with Ubiquitin. <i>Trends in Biochemical Sciences</i> , 2018, 43, 44-60.	3.7	32

#	ARTICLE	IF	CITATIONS
19	TBK1 and IKK $\mu$ prevent TNF-induced cell death by RIPK1 phosphorylation. <i>Nature Cell Biology</i> , 2018, 20, 1389-1399.	4.6	198
20	LUBAC prevents lethal dermatitis by inhibiting cell death induced by TNF, TRAIL and CD95L. <i>Nature Communications</i> , 2018, 9, 3910.	5.8	81
21	Characterization of the TNFR1-SC Using “Modified Tandem Affinity Purification” in Conjunction with Liquid Chromatography–Mass Spectrometry (LC-MS). <i>Methods in Molecular Biology</i> , 2018, 1857, 161-169.	0.4	0
22	Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells. <i>ELife</i> , 2018, 7, .	2.8	20
23	The Linear ubiquitin chain assembly complex acts as a liver tumor suppressor and inhibits hepatocyte apoptosis and hepatitis. <i>Hepatology</i> , 2017, 65, 1963-1978.	3.6	29
24	The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2. <i>Molecular Cell</i> , 2017, 65, 730-742.e5.	4.5	189
25	The linear ubiquitin chain assembly complex regulates TRAIL-induced gene activation and cell death. <i>EMBO Journal</i> , 2017, 36, 1147-1166.	3.5	90
26	Martin Leverkus, 1965–2016. <i>Cell Death Discovery</i> , 2017, 3, 16093.	2.0	0
27	Exploring the TRAILS less travelled: TRAIL in cancer biology and therapy. <i>Nature Reviews Cancer</i> , 2017, 17, 352-366.	12.8	438
28	TLRs Go Linear “ On the Ubiquitin Edge. <i>Trends in Molecular Medicine</i> , 2017, 23, 296-309.	3.5	8
29	A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development. <i>Cancer Cell</i> , 2017, 32, 342-359.e10.	7.7	122
30	TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis. <i>Scientific Reports</i> , 2017, 7, 5514.	1.6	14
31	Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	512
32	Zebrafish Model for Functional Screening of Flow-Responsive Genes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 130-143.	1.1	45
33	Mitochondrial permeabilization engages NF- $\kappa$ B-dependent anti-tumour activity under caspase deficiency. <i>Nature Cell Biology</i> , 2017, 19, 1116-1129.	4.6	181
34	Opposing role of tumor necrosis factor receptor 1 signaling in T cell-mediated hepatitis and bacterial infection in mice. <i>Hepatology</i> , 2016, 64, 508-521.	3.6	21
35	Formation and removal of polyubiquitin chains in the regulation of tumor necrosis factor-induced gene activation and cell death. <i>FEBS Journal</i> , 2016, 283, 2626-2639.	2.2	34
36	Poly-ubiquitination in TNFR1-mediated necroptosis. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 2165-2176.	2.4	130

#	ARTICLE	IF	CITATIONS
37	SPATA2-Mediated Binding of CYLD to HOIP Enables CYLD Recruitment to Signaling Complexes. <i>Cell Reports</i> , 2016, 16, 2271-2280.	2.9	118
38	NEMO regulates a cell death switch in TNF signaling by inhibiting recruitment of RIPK3 to the cell death-inducing complex II. <i>Cell Death and Disease</i> , 2016, 7, e2346-e2346.	2.7	16
39	Linear ubiquitin chain assembly complex coordinates late thymic T-cell differentiation and regulatory T-cell homeostasis. <i>Nature Communications</i> , 2016, 7, 13353.	5.8	47
40	LUBAC deficiency perturbs TLR3 signaling to cause immunodeficiency and autoinflammation. <i>Journal of Experimental Medicine</i> , 2016, 213, 2671-2689.	4.2	79
41	NEMO Prevents RIP Kinase 1-Mediated Epithelial Cell Death and Chronic Intestinal Inflammation by NF- $\kappa$ B-Dependent and -Independent Functions. <i>Immunity</i> , 2016, 44, 553-567.	6.6	157
42	Holding RIPK1 on the Ubiquitin Leash in TNFR1 Signaling. <i>Trends in Cell Biology</i> , 2016, 26, 445-461.	3.6	146
43	Onto better TRAILs for cancer treatment. <i>Cell Death and Differentiation</i> , 2016, 23, 733-747.	5.0	259
44	Linear ubiquitination in immunity. <i>Immunological Reviews</i> , 2015, 266, 190-207.	2.8	124
45	LUBAC-Recruited CYLD and A20 Regulate Gene Activation and Cell Death by Exerting Opposing Effects on Linear Ubiquitin in Signaling Complexes. <i>Cell Reports</i> , 2015, 13, 2258-2272.	2.9	238
46	WHO grade related expression of TRAIL-receptors and apoptosis regulators in meningioma. <i>Pathology Research and Practice</i> , 2015, 211, 109-116.	1.0	11
47	UBE2L3 Polymorphism Amplifies NF- $\kappa$ B Activation and Promotes Plasma Cell Development, Linking Linear Ubiquitination to Multiple Autoimmune Diseases. <i>American Journal of Human Genetics</i> , 2015, 96, 221-234.	2.6	84
48	Cancer Cell-Autonomous TRAIL-R Signaling Promotes KRAS-Driven Cancer Progression, Invasion, and Metastasis. <i>Cancer Cell</i> , 2015, 27, 561-573.	7.7	173
49	Effect of UBE2L3 genotype on regulation of the linear ubiquitin chain assembly complex in systemic lupus erythematosus. <i>Lancet, The</i> , 2015, 385, S9.	6.3	15
50	The Schistosoma mansoni T2 ribonuclease omega-1 modulates inflammasome-dependent IL-1 $\beta$ secretion in macrophages. <i>International Journal for Parasitology</i> , 2015, 45, 809-813.	1.3	34
51	TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. <i>Oncogene</i> , 2015, 34, 2138-2144.	2.6	65
52	Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. <i>Cell Death and Differentiation</i> , 2015, 22, 58-73.	5.0	811
53	Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway. <i>Oncotarget</i> , 2015, 6, 10994-11008.	0.8	13
54	TNFR1-dependent cell death drives inflammation in Sharpin-deficient mice. <i>ELife</i> , 2014, 3, .	2.8	232

#	ARTICLE	IF	CITATIONS
55	Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. <i>Cell Death and Differentiation</i> , 2014, 21, 491-502.	5.0	100
56	Ubiquitin in the immune system. <i>EMBO Reports</i> , 2014, 15, 322-322.	2.0	4
57	Regulation of Death Receptor-Induced Necroptosis by Ubiquitination. , 2014, , 79-97.		0
58	Bortezomib Sensitizes Primary Meningioma Cells to TRAIL-Induced Apoptosis by Enhancing Formation of the Death-Inducing Signaling Complex. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2014, 73, 1034-1046.	0.9	18
59	Nuclear Death Receptor TRAIL-R2 Inhibits Maturation of Let-7 and Promotes Proliferation of Pancreatic and Other Tumor Cells. <i>Gastroenterology</i> , 2014, 146, 278-290.	0.6	101
60	Regulated necrosis: the expanding network of non-apoptotic cell death pathways. <i>Nature Reviews Molecular Cell Biology</i> , 2014, 15, 135-147.	16.1	1,373
61	Ubiquitin in the immune system. <i>EMBO Reports</i> , 2014, 15, 28-45.	2.0	193
62	Getting TRAIL back on track for cancer therapy. <i>Cell Death and Differentiation</i> , 2014, 21, 1350-1364.	5.0	392
63	Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection. <i>Pathology Research and Practice</i> , 2014, 210, 83-91.	1.0	9
64	HOIP Deficiency Causes Embryonic Lethality by Aberrant TNFR1-Mediated Endothelial Cell Death. <i>Cell Reports</i> , 2014, 9, 153-165.	2.9	217
65	Cytosolic and nuclear caspase-8 have opposite impact on survival after liver resection for hepatocellular carcinoma. <i>BMC Cancer</i> , 2013, 13, 532.	1.1	23
66	Necroptosis in Immunity and Ischemia-Reperfusion Injury. <i>American Journal of Transplantation</i> , 2013, 13, 2797-2804.	2.6	150
67	Apoptosis therapy: driving cancers down the road to ruin. <i>Nature Medicine</i> , 2013, 19, 131-133.	15.2	43
68	Death Receptor-Ligand Systems in Cancer, Cell Death, and Inflammation. <i>Cold Spring Harbor Perspectives in Biology</i> , 2013, 5, a008698-a008698.	2.3	177
69	Linear ubiquitination: a newly discovered regulator of cell signalling. <i>Trends in Biochemical Sciences</i> , 2013, 38, 94-102.	3.7	133
70	Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing. <i>Cell Death and Disease</i> , 2013, 4, e719-e719.	2.7	129
71	Cezanne Regulates Inflammatory Responses to Hypoxia in Endothelial Cells by Targeting TRAF6 for Deubiquitination. <i>Circulation Research</i> , 2013, 112, 1583-1591.	2.0	51
72	Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 12024-12029.	3.3	485

#	ARTICLE	IF	CITATIONS
73	No one can whistle a symphony alone – how different ubiquitin linkages cooperate to orchestrate NF- $\kappa$ B activity. <i>Journal of Cell Science</i> , 2012, 125, 549-559.	1.2	50
74	Thiocolchicoside a semi-synthetic derivative of the Glory Lily: a new weapon to fight metastatic bone resorption?. <i>British Journal of Pharmacology</i> , 2012, 165, 2124-2126.	2.7	7
75	The Ubiquitin Ligase XIAP Recruits LUBAC for NOD2 Signaling in Inflammation and Innate Immunity. <i>Molecular Cell</i> , 2012, 46, 746-758.	4.5	336
76	Generation and physiological roles of linear ubiquitin chains. <i>BMC Biology</i> , 2012, 10, 23.	1.7	143
77	Hypochlorite-modified low-density lipoprotein induces the apoptotic machinery in Jurkat T-cell lines. <i>Biochemical and Biophysical Research Communications</i> , 2011, 410, 895-900.	1.0	10
78	TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer. <i>Immunological Reviews</i> , 2011, 244, 9-28.	2.8	200
79	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , 2011, 11, 719-725.	12.8	1,084
80	Linear ubiquitination prevents inflammation and regulates immune signalling. <i>Nature</i> , 2011, 471, 591-596.	13.7	805
81	Caspase-8 and Bid: Caught in the act between death receptors and mitochondria. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2011, 1813, 558-563.	1.9	384
82	The Emerging Role of Linear Ubiquitination in Cell Signaling. <i>Science Signaling</i> , 2011, 4, re5.	1.6	64
83	The Linear Ubiquitin Chain Assembly Complex (LUBAC) Forms Part of the TNF-R1 Signalling Complex and Is Required for Effective TNF-Induced Gene Induction and Prevents TNF-Induced Apoptosis. <i>Advances in Experimental Medicine and Biology</i> , 2011, 691, 115-126.	0.8	13
84	TRAIL Dependent Fratricidal Killing of gp120 Primed Hepatocytes by HCV Core Expressing Hepatocytes. <i>PLoS ONE</i> , 2011, 6, e27171.	1.1	6
85	TRAIL-Rezeptor-Agonisten, eine neue Klasse proapoptotischer Krebstherapeutika. <i>Onkopipeline</i> , 2010, 3, 11-23.	0.0	0
86	Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis. <i>Journal of Neuro-Oncology</i> , 2010, 97, 171-185.	1.4	16
87	Tyrosine phosphatase inhibition triggers sustained canonical serine-dependent NF- $\kappa$ B activation via Src-dependent blockade of PP2A. <i>Biochemical Pharmacology</i> , 2010, 80, 439-447.	2.0	24
88	Differential expression of the TRAIL/TRAIL-receptor system in patients with inflammatory bowel disease. <i>Pathology Research and Practice</i> , 2010, 206, 43-50.	1.0	28
89	Oncogenic K-Ras Turns Death Receptors Into Metastasis-Promoting Receptors in Human and Mouse Colorectal Cancer Cells. <i>Gastroenterology</i> , 2010, 138, 2357-2367.	0.6	130
90	Polymeric Substrates with Tunable Elasticity and Nanoscopically Controlled Biomolecule Presentation. <i>Langmuir</i> , 2010, 26, 15472-15480.	1.6	75

#	ARTICLE	IF	CITATIONS
91	Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib. <i>British Journal of Cancer</i> , 2010, 102, 1707-1716.	2.9	70
92	CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling. <i>Journal of Experimental Medicine</i> , 2009, 206, 1379-1393.	4.2	39
93	TRAF2 Must Bind to Cellular Inhibitors of Apoptosis for Tumor Necrosis Factor (TNF) to Efficiently Activate NF- $\kappa$ B and to Prevent TNF-induced Apoptosis. <i>Journal of Biological Chemistry</i> , 2009, 284, 35906-35915.	1.6	202
94	Prognostic Value of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 650-659.	3.2	59
95	Small Molecule XIAP Inhibitors Enhance TRAIL-Induced Apoptosis and Antitumor Activity in Preclinical Models of Pancreatic Carcinoma. <i>Cancer Research</i> , 2009, 69, 2425-2434.	0.4	140
96	From Biochemical Principles of Apoptosis Induction by TRAIL to Application in Tumour Therapy. <i>Results and Problems in Cell Differentiation</i> , 2009, 49, 115-143.	0.2	4
97	Is TRAIL the holy grail of cancer therapy?. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2009, 14, 607-623.	2.2	115
98	Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. <i>Journal of Molecular Medicine</i> , 2009, 87, 995-1007.	1.7	72
99	Micro-Nanostructured Protein Arrays: A Tool for Geometrically Controlled Ligand Presentation. <i>Small</i> , 2009, 5, 1014-1018.	5.2	49
100	Following TRAIL's path in the immune system. <i>Immunology</i> , 2009, 127, 145-154.	2.0	254
101	Recruitment of the Linear Ubiquitin Chain Assembly Complex Stabilizes the TNF-R1 Signaling Complex and Is Required for TNF-Mediated Gene Induction. <i>Molecular Cell</i> , 2009, 36, 831-844.	4.5	674
102	TRAIL and Other TRAIL Receptor Agonists as Novel Cancer Therapeutics. <i>Advances in Experimental Medicine and Biology</i> , 2009, 647, 195-206.	0.8	80
103	CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling. <i>Journal of Cell Biology</i> , 2009, 185, i13-i13.	2.3	0
104	Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. <i>Oncogene</i> , 2008, 27, 3211-3220.	2.6	89
105	Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. <i>Cell Death and Differentiation</i> , 2008, 15, 762-772.	5.0	191
106	NF- $\kappa$ B Inhibition Reveals Differential Mechanisms of TNF Versus TRAIL-Induced Apoptosis Upstream or at the Level of Caspase-8 Activation Independent of cIAP2. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1134-1147.	0.3	61
107	Death receptors as targets for anti-cancer therapy. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 2566-2585.	1.6	58
108	Targeting XIAP Bypasses Bcl-2-Mediated Resistance to TRAIL and Cooperates with TRAIL to Suppress Pancreatic Cancer Growth <i>In vitro</i> and <i>In vivo</i> . <i>Cancer Research</i> , 2008, 68, 7956-7965.	0.4	143

#	ARTICLE	IF	CITATIONS
109	Troglitazone-mediated sensitization to TRAIL-induced apoptosis is regulated by proteasome-dependent degradation of FLIP and ERK1/2-dependent phosphorylation of BAD. <i>Cancer Biology and Therapy</i> , 2008, 7, 1982-1990.	1.5	14
110	Biochemical Analysis of the Native TRAIL Death-Inducing Signaling Complex. , 2008, 414, 221-239.		54
111	TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. <i>Journal of Clinical Investigation</i> , 2008, 118, 100-110.	3.9	159
112	Bortezomib-Mediated Up-Regulation of TRAIL-R1 and TRAIL-R2 Is Not Necessary for but Contributes to Sensitization of Primary Human Glioma Cells to TRAIL. <i>Clinical Cancer Research</i> , 2007, 13, 6541-6542.	3.2	8
113	Lidocaine Induces Apoptosis via the Mitochondrial Pathway Independently of Death Receptor Signaling. <i>Anesthesiology</i> , 2007, 107, 136-143.	1.3	117
114	TRAIL signalling: Decisions between life and death. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1462-1475.	1.2	408
115	Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis. <i>Clinical Cancer Research</i> , 2007, 13, 3403-3412.	3.2	115
116	Protective effect of <i>Mangifera indica</i> L. polyphenols on human T lymphocytes against activation-induced cell death. <i>Pharmacological Research</i> , 2007, 55, 167-173.	3.1	26
117	Regulation of Enterocyte Apoptosis by Acyl-CoA Synthetase 5 Splicing. <i>Gastroenterology</i> , 2007, 133, 587-598.	0.6	47
118	TRAIL: a multifunctional cytokine. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 3813.	3.0	114
119	TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. <i>Hepatology</i> , 2007, 45, 649-658.	3.6	108
120	The promise of TRAIL-potential and risks of a novel anticancer therapy. <i>Journal of Molecular Medicine</i> , 2007, 85, 923-935.	1.7	175
121	TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy. <i>Radiotherapy and Oncology</i> , 2006, 80, 214-222.	0.3	34
122	<i>Mangifera indica</i> L. extract protects T cells from activation-induced cell death. <i>International Immunopharmacology</i> , 2006, 6, 1496-1505.	1.7	13
123	Caspases Target Only Two Architectural Components within the Core Structure of the Nuclear Pore Complex*. <i>Journal of Biological Chemistry</i> , 2006, 281, 1296-1304.	1.6	45
124	Cyclooxygenase-2 Inhibition Induces Apoptosis Signaling via Death Receptors and Mitochondria in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2006, 66, 7059-7066.	0.4	151
125	Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs. <i>Clinical Cancer Research</i> , 2006, 12, 2640-2646.	3.2	197
126	Transforming growth factor $\beta^2$ can mediate apoptosis via the expression of TRAIL in human hepatoma cells. <i>Hepatology</i> , 2005, 42, 183-192.	3.6	27



#	ARTICLE	IF	CITATIONS
127	Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. <i>Hepatology</i> , 2005, 42, 588-597.	3.6	165
128	cFLIPL Inhibits Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated NF- $\kappa$ B Activation at the Death-inducing Signaling Complex in Human Keratinocytes. <i>Journal of Biological Chemistry</i> , 2004, 279, 52824-52834.	1.6	46
129	NF- $\kappa$ B-dependent Induction of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) and Fas/FasL Is Crucial for Efficient Influenza Virus Propagation. <i>Journal of Biological Chemistry</i> , 2004, 279, 30931-30937.	1.6	220
130	Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. <i>Nature Medicine</i> , 2004, 10, 389-395.	15.2	217
131	The interplay between the Bcl-2 family and death receptor-mediated apoptosis. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2004, 1644, 125-132.	1.9	178
132	Activated T $\alpha$ 1 killer cells induce apoptosis in lung epithelial cells and the release of pro-inflammatory cytokine TNF- $\alpha$ . <i>European Journal of Immunology</i> , 2004, 34, 1762-1770.	1.6	53
133	Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. <i>International Journal of Cancer</i> , 2004, 109, 281-290.	2.3	85
134	Apoptosis Induction by TRAIL. , 2003, 215, 95-116.		0
135	TRAIL-Induced Apoptosis and Gene Induction in HaCaT Keratinocytes: Differential Contribution of TRAIL Receptors 1 and 2. <i>Journal of Investigative Dermatology</i> , 2003, 121, 149-155.	0.3	59
136	In Chronic Pancreatitis, Widespread Emergence of TRAIL Receptors in Epithelia Coincides with Neoplasia. <i>Laboratory Investigation</i> , 2003, 83, 825-836.	1.7	32
137	Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase Maturation. <i>Molecular and Cellular Biology</i> , 2003, 23, 777-790.	1.1	109
138	TNF-Related Apoptosis-Inducing Ligand Mediates Tumoricidal Activity of Human Monocytes Stimulated by Newcastle Disease Virus. <i>Journal of Immunology</i> , 2003, 170, 1814-1821.	0.4	97
139	CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. <i>Journal of Clinical Investigation</i> , 2003, 111, 1133-1145.	3.9	674
140	T cells require TRAIL for optimal graft-versus-tumor activity. <i>Nature Medicine</i> , 2002, 8, 1433-1437.	15.2	149
141	Sensitive and real-time determination of H2O2 release from intact peroxisomes. <i>Biochemical Journal</i> , 2002, 363, 483.	1.7	29
142	Sensitive and real-time determination of H2O2 release from intact peroxisomes. <i>Biochemical Journal</i> , 2002, 363, 483-491.	1.7	48
143	TRAIL and its receptors in the colonic epithelium: A putative role in the defense of viral infections. <i>Gastroenterology</i> , 2002, 122, 659-666.	0.6	84
144	Lack of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand But Presence of Its Receptors in the Human Brain. <i>Journal of Neuroscience</i> , 2002, 22, RC209-RC209.	1.7	106

#	ARTICLE	IF	CITATIONS
145	TRAIL enhances thymidine kinase/ganciclovir gene therapy of neuroblastoma cells. <i>Cancer Gene Therapy</i> , 2002, 9, 372-381.	2.2	21
146	Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. <i>EMBO Journal</i> , 2002, 21, 4520-4530.	3.5	303
147	T cells require TRAIL for optimal graft-versus-tumor activity. <i>Nature Medicine</i> , 2002, 8, 1433-1437.	15.2	38
148	Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. <i>Clinical Cancer Research</i> , 2002, 8, 3734-40.	3.2	100
149	Targeting the Function of Mature Dendritic Cells by Human Cytomegalovirus. <i>Immunity</i> , 2001, 15, 997-1009.	6.6	203
150	CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. <i>Oncogene</i> , 2001, 20, 4128-4137.	2.6	104
151	CD95 and TRAIL receptor-mediated activation of protein kinase C and NF- $\kappa$ B contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. <i>Oncogene</i> , 2001, 20, 4258-4269.	2.6	154
152	Biochemistry and function of the DISC. <i>Trends in Biochemical Sciences</i> , 2001, 26, 452-453.	3.7	64
153	Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: Sensitivity of human thymocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 5158-5163.	3.3	63
154	Critical role for mitochondria in B cell receptor-mediated apoptosis. <i>European Journal of Immunology</i> , 2000, 30, 69-77.	1.6	59
155	Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. <i>Oncogene</i> , 2000, 19, 5477-5486.	2.6	257
156	Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis. <i>Blood</i> , 2000, 96, 2628-2631.	0.6	84
157	Cutting Edge: Resistance to Apoptosis and Continuous Proliferation of Dendritic Cells Deficient for TNF Receptor-1. <i>Journal of Immunology</i> , 2000, 165, 4792-4796.	0.4	31
158	Fluorogenic Substrates as Detectors of Caspase Activity During Natural Killer Cell-Induced Apoptosis. <i>Journal of Immunology</i> , 2000, 121, 155-162.		3
159	The CD95 (APO-1/Fas) and the TRAIL (APO-2L) Apoptosis Systems. <i>Experimental Cell Research</i> , 2000, 256, 58-66.	1.2	586
160	FADD/MORT1 and Caspase-8 Are Recruited to TRAIL Receptors 1 and 2 and Are Essential for Apoptosis Mediated by TRAIL Receptor 2. <i>Immunity</i> , 2000, 12, 599-609.	6.6	748
161	Failure of Bcl-2 to block cytochrome c redistribution during TRAIL-induced apoptosis. <i>FEBS Letters</i> , 2000, 471, 93-98.	1.3	99
162	Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis. <i>Blood</i> , 2000, 96, 2628-2631.	0.6	10

#	ARTICLE	IF	CITATIONS
163	Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. <i>Cancer Research</i> , 2000, 60, 553-9.	0.4	244
164	Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. <i>Cancer Research</i> , 2000, 60, 3051-7.	0.4	164
165	Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis. <i>Blood</i> , 2000, 96, 2628-31.	0.6	27
166	Herpes Simplex Virus Type 1 Infection of Activated Cytotoxic T Cells. <i>Journal of Experimental Medicine</i> , 1999, 190, 1103-1114.	4.2	104
167	Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. <i>Nature Medicine</i> , 1999, 5, 157-163.	15.2	2,377
168	Letter to the Editor. <i>Cell Death and Differentiation</i> , 1999, 6, 821-822.	5.0	75
169	CD95 Ligand (CD95L) in Normal Human Lymphoid Tissues. <i>American Journal of Pathology</i> , 1999, 154, 193-201.	1.9	36
170	We aim to refresh science, not to rebel. <i>Nature</i> , 1998, 393, 206-206.	13.7	0
171	A regulatory element in the CD95 (APO-1/Fas) ligand promoter is essential for responsiveness to TCR-mediated activation. <i>European Journal of Immunology</i> , 1998, 28, 2373-2383.	1.6	53
172	Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family. <i>Journal of Experimental Medicine</i> , 1997, 186, 1165-1170.	4.2	594
173	TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. <i>EMBO Journal</i> , 1997, 16, 5386-5397.	3.5	1,012
174	Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.. <i>Journal of Clinical Investigation</i> , 1997, 99, 403-413.	3.9	653
175	CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a pathogenetic role for the CD95/CD95 ligand-system in ulcerative colitis. <i>Biochemical Society Transactions</i> , 1996, 24, 614S-614S.	1.6	0
176	Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). <i>Nature</i> , 1995, 373, 438-441.	13.7	1,625
177	Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. <i>Nature</i> , 1995, 375, 497-500.	13.7	1,002
178	Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.. <i>Journal of Experimental Medicine</i> , 1995, 182, 1223-1230.	4.2	721
179	APO-1 (CD95)-dependent and -independent antigen receptor-induced apoptosis in human T and B cell lines. <i>International Immunology</i> , 1995, 7, 1873-1884.	1.8	64
180	Cell surface sialylation plays a role in modulating sensitivity towards APO-1-mediated apoptotic cell death. <i>Cell Death and Differentiation</i> , 1995, 2, 163-71.	5.0	64

#	ARTICLE	IF	CITATIONS
181	Cell nucleus and DNA fragmentation are not required for apoptosis.. Journal of Cell Biology, 1994, 127, 15-20.	2.3	419
182	Structure of the human APO-1 gene. European Journal of Immunology, 1994, 24, 3057-3062.	1.6	148
183	The Role of APO-1-Mediated Apoptosis in the Immune System. Immunological Reviews, 1994, 142, 175-191.	2.8	243
184	The human APO-1 (APT) antigen maps to 10q23, a region that is syntenic with mouse chromosome 19. Genomics, 1992, 14, 179-180.	1.3	47
185	Death Domain-Containing Receptors – Decisions between Suicide and Fire. , 0, , 23-36.		2